Literature DB >> 10717523

Risk of complications from bone metastases in breast cancer. implications for management.

T A Plunkett1, P Smith, R D Rubens.   

Abstract

A retrospective analysis of 859 patients who developed bone metastases from breast cancer between 1975 and 1991 was performed in order to identify factors that predict for complications from skeletal disease. The patients were divided into four groups based on the sites of disease at diagnosis of skeletal metastases: bone disease only; bone and soft tissue disease; bone and pleuro-pulmonary disease; bone and liver disease. Patients with metastatic disease confined to the skeleton were most likely to develop a pathological fracture. The time to long bone fracture was similar for all groups, but the least number of such fractures occurred in patients with bone and liver metastases since their survival was shortest (median: 5.5 months; P<0.001). Patients with bone metastases only were most likely to require radiotherapy to painful osseous deposits (P=0.0001) and most rapidly developed spinal cord compression (P=0.01, data not shown). The results suggest that patients with disease confined to the skeleton at the diagnosis of bone metastases are most likely to develop skeletal-related complications from advanced breast cancer. Such patients may benefit most from treatment with bisphosphonates.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10717523     DOI: 10.1016/s0959-8049(99)00331-7

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  56 in total

1.  Bone morphogenetic protein 4 (BMP4) is required for migration and invasion of breast cancer.

Authors:  Dan Guo; Jiayi Huang; Jianping Gong
Journal:  Mol Cell Biochem       Date:  2011-12-14       Impact factor: 3.396

2.  Retrospective analysis of antitumor effects of zoledronic acid in breast cancer patients with bone-only metastases.

Authors:  Naoki Niikura; Jun Liu; Naoki Hayashi; Shana L Palla; Yutaka Tokuda; Gabriel N Hortobagyi; Naoto T Ueno; Richard L Theriault
Journal:  Cancer       Date:  2011-12-02       Impact factor: 6.860

Review 3.  Recent developments in bisphosphonates for patients with metastatic breast cancer.

Authors:  Mary C Gainford; George Dranitsaris; Mark Clemons
Journal:  BMJ       Date:  2005-04-02

4.  [Establishment of mouse model of bone metastasis of prostate cancer and breast cancer via femoral artery injection of tumor cells].

Authors:  Zhao-Yang Yin; Si-Yong Qi; Xiang Cheng; Liang Guo; Hong-Yu Chen; Ming Shi
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2017-07-20

5.  CORR Insights®: Should the Use of Biologic Agents in Patients With Renal and Lung Cancer Affect Our Surgical Management of Femoral Metastases?

Authors:  Adam S Levin
Journal:  Clin Orthop Relat Res       Date:  2019-04       Impact factor: 4.176

6.  Nuclear factor-kappa B ligand and osteoprotegerin levels in serum and gingival crevicular fluid in patients with bone metastases treated with zoledronic acid.

Authors:  Mevlude Inanc; Leylagul Kaynar; Sukru Enhos; Cigdem Pala; Halit Karaca; Veli Berk; Metin Ozkan; Serdar Sıvgın; Bulent Eser; Mustafa Cetin; Ferhan Elmali
Journal:  Med Oncol       Date:  2014-01-22       Impact factor: 3.064

Review 7.  Current role of bone scan with phosphonates in the follow-up of breast cancer.

Authors:  Lorenzo Maffioli; Luigia Florimonte; Luca Pagani; Ivana Butti; Isabel Roca
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-04-16       Impact factor: 9.236

8.  Quality of life (QOL) and symptom burden (SB) in patients with breast cancer.

Authors:  Julia Hamer; Rachel McDonald; Liying Zhang; Sunil Verma; Angela Leahey; Christine Ecclestone; Gillian Bedard; Natalie Pulenzas; Anchal Bhatia; Ronald Chow; Carlo DeAngelis; Janet Ellis; Eileen Rakovitch; Justin Lee; Edward Chow
Journal:  Support Care Cancer       Date:  2016-09-30       Impact factor: 3.603

9.  A new rat model of bone cancer pain produced by rat breast cancer cells implantation of the shaft of femur at the third trochanter level.

Authors:  Qi Gui; Chengcheng Xu; Liang Zhuang; Shu Xia; Yu Chen; Ping Peng; Shiying Yu
Journal:  Cancer Biol Ther       Date:  2012-12-19       Impact factor: 4.742

Review 10.  Optimal management of bone metastases in breast cancer patients.

Authors:  Mh Wong; N Pavlakis
Journal:  Breast Cancer (Dove Med Press)       Date:  2011-05-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.